Surgical resection of a rare primary retroperitoneal mucinous borderline tumor of Müllerian Origin: A case report

Taylor R. Kavanagh, Nneamaka Nwaoduah, Scott D. Richard, Wilbur B. Bowne, Norman G. Rosenblum

Primary retroperitoneal mucinous tumors (PRMTs) are a group of rare neoplasms that consist of three subtypes: mucinous cystadenomas, mucinous borderline tumors or tumors of low malignant potential, and mucinous carcinoma. While the pathogenesis remains unclearly defined, PRMTs are believed to arise from mucinous metaplasia of invaginated mesothelium into the retroperitoneum. These rare tumors largely resemble their ovarian counterparts; however, they lack evidence of ovarian tissue upon pathologic review. Establishing a diagnosis of PRMTs preoperatively is challenging, as diagnosis largely occurs in the postoperative setting. Herein, we report the case of a 60-year-old female who presented with abdominal distention, pelvic pain, and bloating postoperatively remains without evidence of disease recurrence (Fig. 1). The tumor was composed of mucinous gastrointestinal-type epithelium with mild to moderate cytologic atypia, nuclear crowding or stratification, and goblet cells. There was no evidence of invasion into surrounding dense fibrous stroma. No ovarian tissue was identified. Immunohistochemical stains showed tumor cells positive for CK7 (strong, diffuse), PAX8 (patchy), and CK20 (focal), and negative for CDX2 and SATB2. Pathological findings supported a diagnosis of a mucinous borderline tumor of Müllerian origin. Postoperative course was uneventful and the patient discharged on the second postoperative day. Follow-up imaging of the abdomen and pelvis seven months postoperatively remains without evidence of disease recurrence (Fig. 1).

3. Discussion

Primary retroperitoneal mucinous tumors (PRMTs) are a group of rare neoplasms that consist of three subtypes: mucinous cystadenomas, mucinous borderline tumors of low malignant potential, and mucinous cystadenomas, mucinous borderline tumors of low malignant potential, and mucinousexpression of CDX2 and SATB2. Pathological findings supported a diagnosis of a mucinous borderline tumor of Müllerian origin. Postoperative course was uneventful and the patient discharged on the second postoperative day. Follow-up imaging of the abdomen and pelvis seven months postoperatively remains without evidence of disease recurrence (Fig. 1).

3. Discussion

Primary retroperitoneal mucinous tumors (PRMTs) are a group of rare neoplasms that consist of three subtypes: mucinous cystadenomas, mucinous borderline tumors of low malignant potential, and mucinous carcinoma. While the pathogenesis remains unclearly defined, PRMTs are believed to arise from mucinous metaplasia of invaginated mesothelium into the retroperitoneum. These rare tumors largely resemble their ovarian counterparts; however, they lack evidence of ovarian tissue upon pathologic review. Establishing a diagnosis of PRMTs preoperatively is challenging, as diagnosis largely occurs in the postoperative setting. Herein, we report the case of a 60-year-old female who presented with abdominal distention, pelvic pain, and bloating postoperatively remains without evidence of disease recurrence (Fig. 1). The tumor was composed of mucinous gastrointestinal-type epithelium with mild to moderate cytologic atypia, nuclear crowding or stratification, and goblet cells. There was no evidence of invasion into surrounding dense fibrous stroma. No ovarian tissue was identified. Immunohistochemical stains showed tumor cells positive for CK7 (strong, diffuse), PAX8 (patchy), and CK20 (focal), and negative for CDX2 and SATB2. Pathological findings supported a diagnosis of a mucinous borderline tumor of Müllerian origin. Postoperative course was uneventful and the patient discharged on the second postoperative day. Follow-up imaging of the abdomen and pelvis seven months postoperatively remains without evidence of disease recurrence (Fig. 1).

3. Discussion

Primary retroperitoneal mucinous tumors (PRMTs) are a group of rare neoplasms that consist of three subtypes: mucinous cystadenomas, mucinous borderline tumors of low malignant potential, and mucinous carcinoma. While the pathogenesis remains unclearly defined, PRMTs are believed to arise from mucinous metaplasia of invaginated mesothelium into the retroperitoneum. These rare tumors largely resemble their ovarian counterparts; however, they lack evidence of ovarian tissue upon pathologic review. Establishing a diagnosis of PRMTs preoperatively is challenging, as diagnosis largely occurs in the postoperative setting. Herein, we report the case of a 60-year-old female who presented with abdominal distention, pelvic pain, and bloating postoperatively remains without evidence of disease recurrence (Fig. 1). The tumor was composed of mucinous gastrointestinal-type epithelium with mild to moderate cytologic atypia, nuclear crowding or stratification, and goblet cells. There was no evidence of invasion into surrounding dense fibrous stroma. No ovarian tissue was identified. Immunohistochemical stains showed tumor cells positive for CK7 (strong, diffuse), PAX8 (patchy), and CK20 (focal), and negative for CDX2 and SATB2. Pathological findings supported a diagnosis of a mucinous borderline tumor of Müllerian origin. Postoperative course was uneventful and the patient discharged on the second postoperative day. Follow-up imaging of the abdomen and pelvis seven months postoperatively remains without evidence of disease recurrence (Fig. 1).

3. Discussion

Primary retroperitoneal mucinous tumors (PRMTs) are a group of rare neoplasms that consist of three subtypes: mucinous cystadenomas, mucinous borderline tumors of low malignant potential, and mucinos
carcinoma. To our knowledge, there are approximately 150 cases reported in the world literature, to date. PRMTs are typically asymptomatic with clinical manifestations arising as they enlarge, with the most common symptoms related to mass effect including abdominal distention and pain (Myriokefalitaki et al., 2016). Vastly occurring in women, PRMTs presenting in males are rarely described (Thamboo et al., 2006; Benkirane et al., 2009).

Herein, we discuss the case of a 60-year-old female who presented with several months of abdominal distension, post-prandial bloating, and pelvic pain, later found to have a large cystic mass on imaging and subsequently underwent surgical resection (Fig. 1). Histopathologic evaluation confirmed the presence of a mucinous neoplasm that was morphologically and phenotypically Müllerian in origin, staining positive for CK7 and PAX8 on immunohistochemistry; however, lacking pathologic evidence of true ovarian tissue (Fig. 2). Notably, the patient had grossly normal ovaries and adnexa during the time of surgery. Importantly, features of malignancy including marked cytologic atypia, confluent or solid tumor growth, and stromal invasion were absent.

Histologically, these tumors resemble ovarian mucinous neoplasms; however, lack of true ovarian tissue is requisite for pathologic confirmation (Bifulco et al., 2008; Subramony et al., 2001). Indeed, the origin of these tumors is largely unknown, with three theories of pathogenesis predominating. One theory proposes that these tumors arise from a teratoma with overgrowth of the mucinous component, while another favors a neoplasm originating from heterotopic ovarian tissue (Acharya et al., 2016; Paraskevakou et al., 2014; Roma and Malpica, 2009). This latter etiology holds less favor as most reports note an absence of associated ovarian stroma. The most widely supported etiology favors mucinous metaplasia of the overlying peritoneal mesothelium with resultant cystic mass formation (Subramony et al., 2001; Tenti et al., 1994; Issi et al., 2004). This is based on precedent that peritoneal mesothelium has potential for Müllerian differentiation. Another possibility is that these tumors may originate from remnants of the embryonal urogenital apparatus.

Confirming diagnosis of these tumors preoperatively is challenging with the rarity of presentation and lack of objective radiographic criteria and diagnostic surrogates. Notably, fine needle aspiration of PRMTs and evaluation of aspirated fluid typically provides a paucity of diagnostic information (Cabello Benavente et al., 2017). Consequently, definitive diagnosis requires surgical resection. At our institution, multidisciplinary consensus remains that if an abdominal mass (solid or cystic) is concerning for premalignancy and/or potentially harbors a cancer, and patient performance status and mass appear amenable to complete surgical removal with curative intent, we typically advocate for upfront resection without preoperative biopsy. A preoperative biopsy of a large cystic lesion without solid components is not recommended. This is particularly relevant in our patient with a symptomatic resectable cystic mass. Importantly, this approach obviates potential biopsy-related risks for spillage and/or iatrogenic tumor cell dissemination. Indeed, PRMT is a diagnosis of exclusion, with more frequently encountered epithelial tumors located in the retroperitoneum including ovarian, gastrointestinal, renal cancers and advanced disease metastases. In cases when a

Fig. 1. A-B Contrast-enhanced preoperative CT scan of the 18 cm fluid-filled cystic mass in the left abdomen (A coronal, B axial) concerning for potential malignancy. C-D Contrast-enhanced CT scan 7 months postoperatively demonstrating no evidence of recurrent disease (A coronal, B axial).
rare, mucin–containing neoplasm is encountered, potential for synchronous colorectal malignancies can occur which necessitates surveillance colonoscopy in appropriate female at-risk patients (Morano et al., 2018).

In general, patients with resectable retroperitoneal masses concerning for malignancy are candidates for surgery with curative intent. Operative treatment includes open and/or minimally invasive strategies that permit careful, safe resection and simultaneous inspection for synchronous disease (Cabello Benavente et al., 2017; Foula et al., 2019). Importantly, cystic fluid has potential to harbor malignant cells, thus surgeons must take extreme care to avoid iatrogenic rupture of the mass during resection. Postoperative treatment considerations are contingent upon pathological review. In our case, this patient with a borderline mucinous tumor underwent surgical resection followed by multidisciplinary recommendation for annual surveillance imaging, thereafter.

Currently, there are no consensus guidelines regarding postsurgical follow-up and surveillance for PRMTs; long-term prognosis for patients with mucinous cystadenomas and mucinous borderline tumors remains favorable, with a 5-year survival reportedly nearing 100% (Wolf et al., 2017). Adjuvant therapy is rarely indicated for borderline tumors (Dayan et al., 2016). In contrast, patients with a diagnosis of mucinous cystadenocarcinoma with reported 5-year survival of 68% necessitates important considerations and strategies for adjuvant therapy (Wolf et al., 2017). Notably, treatment approaches that include hysterectomy, salpingo-oophorectomy, and adjuvant systemic therapy have yet to yield demonstrable survival benefit for this biologically aggressive variant of PRMT.

4. Conclusion

This case report demonstrates a rare patient with a primary retroperitoneal mucinous borderline tumor diagnosed by histopathology after surgical resection. We highlight the importance for consideration of primary retroperitoneal mucinous tumors (PRMTs) in the differential diagnosis when encountering retroperitoneal cystic lesions. Surgical resection provides durable disease control for mucinous borderline tumors or tumors of low malignant potential, as seen in our patient and reported in the existing literature. Limitations of this case report include the retrospective nature of this review, duration of follow-up, and requirement for more conclusive, larger patient outcome studies to validate this treatment strategy.

5. Consent

Written consent was obtained from the patient for publication of this case report.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Acharya, S.R., Dasgupta, P., Das, S., Halder, S., Panda, N., 2016. Retrropancreatic Ovarian Tumor. Indian J. Surg. 78 (3), 232–234.
Benkirane, A., Mikou, A., Jahid, A., Zouaidia, F., Laraqui, L., Bernounsi, Z., Mahassini, N., 2009. Primary retroperitoneal mucinous cystadenoma with borderline malignancy in a male patient: a case report. Cases J. 2 (1).
Bifulco, G., Mandato, V.D., Giampaolino, P., Nappi, C., De Cecio, R., Insabato, L., et al., 2008. Huge primary retroperitoneal mucinous cystadenoma of borderline malignancy mimicking an ovarian mass: case report and review. Anticancer Res. 28 (4C), 2309–2315.
Cabello Benavente, R.A.G., Quicios Dorado, C., Gomis Goti, C., Castro, R., Mateo, M., Garcia Fernandez, E., Gonzalez, E.C., 2017. Laparoscopic Approach for a Mucinous Mullerian Retropertioneal Cystadenoma. J. Obs. & Gynec. 1 (4).
Dayan, D., Abu-Abeid, S., Klausner, J.M., Sagie, B., 2016. Primary Retroperitoneal Mucinous Cystic Neoplasm: Authors’ Experience and Review of the Literature. Am. J. Clin. Oncol. 39 (5), 433–440.

Foula, M.S., AlQattan, A.S., AlQurashi, A.M., AlShaqaq, H.M., Mirza Gari, M.K., 2019. Incidentally discovered huge retroperitoneal mucinous cystadenoma with successful laparoscopic management: Case report. Int. J. Surg. Case Rep. 61, 242–245.

Isse, K., Harada, K., Suzuki, Y., Ishiguro, K., Sasaki, M., Kajiwara, S., Nakanuma, Y., 2004. Retroperitoneal mucinous cystadenoma: report of two cases and review of the literature. Pathol. Int. 54 (2), 132–138.

Morano, W.F., Gleeson, E.M., Sullivan, S.H., Padmanaban, V., Mapow, B.L., Shewokis, P.A., et al., 2018. Clinicopathological Features and Management of Appendiceal Mucocoeles: A Systematic Review. Am. Surg. 84 (2), 273–281.

Myriokefalitaki, E., Luqman, I., Potdar, N., Brown, L., Steward, W., Moss, E.L., 2016. Primary retroperitoneal mucinous cystadenocarcinoma (PRMCa): a systematic review of the literature and meta-analysis. Arch. Gynecol. Obstet. 293 (4), 709–720.

Paraskevakou, H., Orfanos, S., Diamantis, T., Konstantinidou, A., Patsouris, E., 2014. Primary retroperitoneal mucinous cystadenoma. A rare case with two cysts and review of the literature. Hippokratia. 18 (3), 278–281.

Roma, A.A., Malpica, A., 2009. Primary retroperitoneal mucinous tumors: a clinicopathologic study of 18 cases. Am. J. Surg. Pathol. 33 (4), 526–533.

Subramony, C., Hahmpton, S., Hashimoto, L.A., 2001. Retroperitoneal mucinous cystadenoma. Arch. Pathol. Lab. Med. 125 (5), 691–694.

Tentí, P., Romagnoli, S., Pellegrato, N.S., Zappatore, R., Giunta, P., Ranzani, G.N., et al., 1994. Primary retroperitoneal mucinous cystadenocarcinoma: an immunohistochemical and molecular study. Virchows Arch. 424 (1), 53–57.

Thamboo, T.F., Sim, R., Tan, S.Y., Yap, W.M., 2006. Primary retroperitoneal mucinous cystadenocarcinoma in a male patient. J. Clin. Pathol. 59 (6), 655–657.

Wolf, B., Kunert, C., Horn, L.C., Einenkel, J., 2017. Management of Primary Retroperitoneal Mucinous Tumors: A Retrospective Meta-Analysis. Int. J. Gynecol. Cancer. 27 (6), 1064–1071.